Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Supriya Lifescience Ltd Fundamentals

Market Cap
₹ 3068.41 Cr
P/E Ratio (TTM)
25.48
P/B Ratio
4.07
Debt to Equity
0.04
ROE
13.67
EPS (TTM)
14.96
Dividend Yield
0.16 %
Book Value
93.58

Click here to know more about Fundamentals

Supriya Lifescience Ltd Financials

Supriya Lifescience Ltd Financials

Supriya Lifescience Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 68.30 % 68.30 % 68.30 % 68.30 %
Retail 17.06 % 17.50 % 16.10 % 15.39 %
Others 9.23 % 9.60 % 8.52 % 8.44 %
FII 5.36 % 4.56 % 5.34 % 5.73 %
Mutual Funds 0.05 % 0.04 % 1.74 % 2.14 %

Promoters

68.30%

Retail

17.06%

Others

9.23%

FII

5.36%

Mutual Funds

0.05%

Promoters

68.30%

Retail

17.50%

Others

9.60%

FII

4.56%

Mutual Funds

0.04%

Promoters

68.30%

Retail

16.10%

Others

8.52%

FII

5.34%

Mutual Funds

1.74%

Promoters

68.30%

Retail

15.39%

Others

8.44%

FII

5.73%

Mutual Funds

2.14%

Resistance and Support

₹380.00

PIVOT

resistance-arrow
Resistance
First Resistance₹383.700
Second Resistance₹385.700
Third Resistance₹389.400
support-arrow
Support
First Support₹378.000
Second Support₹374.300
Third Support₹372.300

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day104,55616,72762.89
Week26,59945,704-69.20
1 Month26,599188,342-69.20
6 Months67,480,14625,678,35544.04

About Supriya Lifescience Ltd

The company was incorporated as Supriya Lifescience Limited on 26 March 2008 upon the conversion of M/s Supriya Chemicals,a partnership firm, into a public limited company.The company commenced operations on 01 April 2008.The company is engaged in manufacturing and export of active pharmaceutical ingredients(APIs).The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. As of 31 March 2021,the company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The company's products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company's business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022. The new clean rooms will add manufacturing capacity of 215 KL per day. On 31 March 2012,the company has issued and allotted 3002400 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 12:1. On 31 March 2013,the company has issued and allotted 1626302 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 1:2. On 01 October 2015,the company has issued and allotted 9757804 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 2:1 On 26 December 2020,the company has sub-divided its face value of equity shares from Rs 10 each to Rs 2 each. During the month of December 2021,the company came out with an Rs 700-crore public issue which comprised of a fresh issue of Rs 200 crore and an offer for sale(OFS) of Rs 500 crore by the promoter Satish Waman Wagh.The IPO shares were allotted at the price of Rs 274 per share including a premium of Rs 272 per share.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India Ltd(NSE) on 28 December 2021.

Managing Director

2008

Founded

Satish Waman Wagh

NSE Symbol

SUPRIYA

Supriya Lifescience Ltd Management

NameDesignation
Satish Waman WaghChairman & Managing Director
Smita Satish WaghWhole-time Director
Soloni Satish WaghWhole-time Director
Shivani Satish WaghWhole-time Director
Balasahab Gulabrao SawantWhole-time Director
Kedar Shankar KarmarkarIndependent Director
Bhairav Manojbhai ChokshiIndependent Director
Dileep Kumar JainIndependent Director
Dinesh N ModiIndependent Director
Neelam Yashpal AroraIndependent Director
Shweta Shivdhari SinghCompany Sec. & Compli. Officer
Manoj Deo DorlikarWhole-time Director

Events

Dividend Announcement for Supriya Lifescience Ltd - May 26, 2023

On May 26, 2023, shareholders are set to receive a dividend payout, with each share entitling its holder to a dividend of 30.0%. This dividend percentage reflec...

Read More

Supriya Lifescience Ltd News

Supriya Lifescience standalone net profit rises 212.92% in the December 2023 quarter
Sales rise 33.22% to Rs 140.07 crore
Supriya Lifesciences to discuss results
On 7 February 2024
Supriya Lifescience standalone net profit rises 41.64% in the September 2023 quarter
Sales rise 24.90% to Rs 140.10 crore
Supriya Lifesciences to conduct board meeting
On 7 November 2023
Supriya Lifesciences to hold AGM
On 29 September 2023
Supriya Lifescience fixes record date for dividend
Recordd date is 15 September 2023
Supriya Lifescience standalone net profit rises 12.91% in the June 2023 quarter
Sales rise 30.25% to Rs 132.02 crore
Supriya Lifesciences to table results
On 3 August 2023
Board of Supriya Lifesciences recommends final dividend
Of Rs 0.6 per share
Supriya Lifescience standalone net profit declines 17.27% in the March 2023 quarter
Sales decline 21.51% to Rs 142.27 crore

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Sun Pharmaceuticals Industries Ltd₹ 367554.12 Cr
₹ 1,531.90
(0.03 %)
89.16
Cipla Ltd₹ 113362.29 Cr
₹ 1,404.05
(0.36 %)
30.52
Zydus Lifesciences Ltd₹ 111083.2 Cr
₹ 1,103.95
(5.00 %)
41.35
Divis Laboratories Ltd₹ 104302.61 Cr
₹ 3,929.00
(0.47 %)
76.42
Dr Reddys Laboratories Ltd₹ 96948.1 Cr
₹ 5,811.60
(0.21 %)
22.34

Supriya Lifescience Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Supriya Lifescience Ltd shares in BlinkX

Supriya Lifescience Ltd's P/E ratio is 25.48 times as of May 18, 2024 at 01:44 PM.

Supriya Lifescience Ltd's most recent financial reports indicate a price-to-book ratio of 4.07, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Supriya Lifescience Ltd's market is 3,068 Cr as on May 18, 2024 at 01:44 PM.

The current financial records of Supriya Lifescience Ltd show a 13.67% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Supriya Lifescience Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

As of the Mar 2024 quarter, the promoter shareholding in Supriya Lifescience Ltd stands at 68.30%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 4.56% to 5.36%.